UNASSIGNED: Post-surgical surveillance of non-functioning @entity977 (NFPA) is based on magnetic resonance imaging (MRI) at 3 or 6 months then 1 year. When there is no adenomatous residue, annual surveillance is recommended for 5 years and then at 7, 10 and 15 years. In case of residue or doubtful MRI, prolonged annual surveillance monitors any progression. Reintervention is indicated if complete residue resection is feasible, or for symptomatic optic pathway compression, to create a safety margin between the @entity5 and the optic pathways ahead of complementary @entity1161 ( @entity1161 ), or in case of post- @entity1161 progression. In case of residue, unless the @entity5 displays elevated growth potential, it is usually recommended to postpone @entity1161 until progression is manifest, as efficacy is comparable whether treatment is immediate or postponed. The efficacy of the various @entity1161 techniques in terms of @entity5 volume control is likewise comparable. @entity1161 -induced @entity4614 is frequent, whatever the technique. The choice thus depends basically on residue characteristics: size, delineation, and proximity to neighboring radiation-sensitive structures. Reduced rates of @entity455 and secondary @entity1313 can be hoped for with one-dose or hypofractionated stereotactic @entity1161 , but there has been insufficient follow-up to provide evidence. @entity1943 analogs and dopaminergic agonists have yet to demonstrate sufficient efficacy. @entity2903 is an option in aggressive NFPA resistant to surgery and @entity1161 .

Post-surgical management of non-functioning XXXX .

@entity455 :: ('MESH:D014652', 'Disease') :: ['vascular complications'] @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT'] @entity4614 :: ('MESH:D007018', 'Disease') :: ['hypopituitarism'] @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenoma'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['Temozolomide'] @entity1943 :: ('MESH:D013004', 'Chemical') :: ['Somatostatin']
@entity977 :: (MESH:D010911,Disease) :: ['pituitary adenoma']
